UPC APP 17784/2025

—·EP4183412: RSV F PROTEIN COMPOSITIONS AND METHODS FOR MAKING SAME

Verfahrensdetails: Status
—
Verfahrensart
Verfahrensantrag
Kategorie
Rücknahmeanträge
Parteien: Kläger
Pfizer, Inc.
Pfizer Europe MA EEIG
Pfizer B.V.
Pfizer S.A.
Pfizer Manufacturing Belgium NV
Pfizer Service Company S.R.L.
Pfizer Pharma GmbH
Pfizer Limited
Vertreter: Gareth Williams (Marks & Clerk LLP)
Beklagte
GlaxoSmithKline Biologicals SA
Vertreter: Oliver Jan Juengst (Bird & Bird LLP); Daniela Kinkeldey (Bird & Bird LLP)
Division: Milan CD
Richter: Andrea Postiglione · Presiding Judge
Anna-Lena Klein · Judge-Rapporteur
Steen Wadskov-Hansen · Technically Qualified Judge
Technology: Biotechnology
Sprache: —
Erste Entscheidung: 22. Apr. 2025

Entscheidungen

2025-04-22
ZurückgenommenApplication Rop 265
Order by Milan Central Division (UPC_CFI_687/2024, 22 April 2025) permitting Pfizer's withdrawal of the revocation action and counterclaim for revocation against GlaxoSmithKline's EP 4 183 412 (RSV F protein vaccine), and permitting GlaxoSmithKline to withdraw its patent amendment application. 60% court fee reimbursement was granted; each party bears its own costs.
Rechtsfragen:Withdrawal of revocation action (R. 265 RoP)Withdrawal of application to amend patent (R. 30, 49 RoP)60% court fee reimbursement

Dokumente